Impact of COVID-19 Infection on the Incidence of Ventilator-acquired

Status Completed

Clinical Trial Summary

Observational cohort study aiming at comparing the incidence of ventilator-associated lower respiratory tract infections between COVID-19 patients and two control groups: one with influenza pneumonia and the other with no viral pneumonia.

Clinical Trial Description

COVAPID is a multicenter cohort study with two retrospective control groups. No intervention will be performed in included patients, only patient characteristics and data on VA-LRTI will be collected.

Patients with confirmed SARS-CoV-2 community-acquired pneumonia, admitted to the participating ICUs from the start of COVID epidemic will be eligible for this study. Those admitted before the beginning of this study will be included retrospectively, and those admitted after the beginning of the study will be included prospectively. 10-20 patients per center will be included in this group. SARSCoV2 infection will be confirmed by a nasopharyngeal PCR or respiratory secretions (tracheal aspirate or bronchoalveolar lavage) PCR. Two retrospective groups will be constituted in order to give some insight of potential impact of SARS-CoV2 infection on the incidence of VALRTI :1) Influenza group : patients with influenza (A or B) community-acquired pneumonia. All patients with influenza community acquired pneumonia and admitted in the same ICU will be eligible in this group.

The number of patients included in this group per center will be similar as that of patients included in the SARS-CoV-2 pneumonia group (10-20 patients). These consecutive patients will by identified using the files of Virology Lab. The first included patient will be the last of the current influenza season (2019-2020), and others will be taken consecutively back to 2019 of 2018 if necessary. PCR (nasopharyngeal or respiratory secretions) confirmation of influenza (A ou B) is required for patients in this group. 2) No viral infection group: patients with no viral community acquired pneumonia. All patients receiving invasive mechanical ventilation for more than 48h before COVID epidemic, for any reason other than viral pneumonia are eligible for this group. The number of included patients in this group will be similar as that of patients included in the SARS-CoV-2 group in the same center (10-20 patients) These consecutive patients will be included starting at the end of January 2020 and going back to 2019 if necessary. VAT and VAP are defined using clinical, radiological and quantitative microbiological criteria. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04359693
Study type	Observational
Source	University Hospital, Lille
Contact
Status	Completed
Phase
Start date	April 22, 2020
Completion date	July 1, 2020

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04410510` - P2Et Extract in the Symptomatic Treatment of Subjects With COVID-19	Phase 2/Phase 3
Withdrawn	`NCT04456426` - Characteristics of Patients With COVID-19 in Meta State, Colombia
Suspended	`NCT04385771` - Cytokine Adsorption in Patients With Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation	N/A
Terminated	`NCT04435457` - Cardiovascular Implications of COVID-19
Withdrawn	`NCT04386447` - Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19	Phase 2
Completed	`NCT04357834` - WAVE. Wearable-based COVID-19 Markers for Prediction of Clinical Trajectories
Completed	`NCT04405934` - COG-UK Project Hospital-Onset COVID-19 Infections Study	N/A
Completed	`NCT04615936` - Nasal Photodisinfection COVID-19 Proof of Concept Study	N/A
Completed	`NCT04369794` - COVID-19: BCG As Therapeutic Vaccine, Transmission Limitation, and Immunoglobulin Enhancement	Phase 4
Terminated	`NCT04401410` - Anti-SARS Cov-2 T Cell Infusions for COVID 19	Phase 1
Completed	`NCT04542850` - Pilot Study to Evaluate the Safety, Tolerability, and Efficacy of 5-ALA-Phosphate + SFC in Subjects With COVID-19	N/A
Completed	`NCT04382040` - A Phase II, Controlled Clinical Study Designed to Evaluate the Effect of ArtemiC in Patients Diagnosed With COVID-19	Phase 2
Completed	`NCT04378582` - Characteristics and Outcomes of Patients With COVID-19 Admitted to the ICU
Completed	`NCT04366908` - Prevention and Treatment With Calcifediol of COVID-19 Induced Acute Respiratory Syndrome	Phase 2
Completed	`NCT04383587` - Seroprevalence of SARS CoV 2 Antibodies in Previously Undiagnosed Healthcare Workers	N/A
Recruiting	`NCT04402814` - IgG/IgM Antibody Test in Patients Who Have Tested Negative or Positive for COVID-19 With the Standard Method of COVID19 Testing.
Completed	`NCT04374565` - Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia	Phase 2
Completed	`NCT04395924` - Maternal-foetal Transmission of SARS-Cov-2
Completed	`NCT04425889` - COVID-19 Antibodies Among Healthcare Workers
Not yet recruiting	`NCT04405492` - Evaluation of Rapid Diagnostic Solutions, Serological and Molecular Tests for COVID-19	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Impact of COVID-19 Infection on the Incidence of Ventilator-acquired Infections — COVAPID

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms